Jiayue pharmaceutical completed nearly 200 million yuan of B + round financing and promoted the mid and late stage clinical projects of innovative drug pipeline

Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing

Academician Pan Yi and Professor Shen Bairong joined the Weiwei science and technology strategy committee

Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1

Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped

The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested

Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases

Medtronic's world's first self expanding pulmonary valve was first-class recalled

Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use

The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.

Yanye said that its Xinguan oral drug s-217622 can quickly eliminate the virus

Bojian abandons Alzheimer's disease drug aduhelm and goes public in the EU

Upside foods, a cell meat enterprise, received US $400 million in financing, the highest single transaction in the industry

Lingfu biology, an experimental animal research service provider, completed a pre-A round of financing of more than 200 million yuan

Hefei Tiangang immunopharmaceutical Co., Ltd., a tumor immunotherapy enterprise, completed a round of pre-A financing of hundreds of millions of yuan

Ping An Health's 2021 annual report was released, with a revenue of 7.3 billion yuan, a year-on-year increase of 8%